Evidence map›Paper›PMID 37759076›Full record

ArticleInternational journal of hematology2023

Regulation of von Willebrand factor by ADAMTS13 ameliorates lipopolysaccharide-induced lung injury in mice.

Yu Onodera, Seiji Mitani, Chihiro Hosoda, Yoko Takabayashi, Asuka Sakata, Ryohei Kawasaki, Ryota Mori, Chiaki Ohshima, Kenji Nishio, Mitsuhiko Sugimoto and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. The pathogenesis of cancer-associated thrombosis.International journal of hematology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Yu OnoderaAdvanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
Seiji MitaniAdvanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
Chihiro HosodaAdvanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
Yoko TakabayashiAdvanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
Asuka SakataMedicinal Biology of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Japan.
Ryohei KawasakiAdvanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
Ryota MoriAdvanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
Chiaki OhshimaAdvanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
Kenji NishioDepartment of General Medicine, Nara Medical University, Kashihara, Japan.
Mitsuhiko SugimotoDepartment of General Medicine, Nara Medical University, Kashihara, Japan.
Kenji SoejimaKM Biologics Co Ltd., Kikuchi, Japan.
Nigel MackmanDepartment of Medicine, Division of Hematology, UNC Blood Research Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Midori ShimaMedicinal Biology of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Japan.
Kohei TatsumiAdvanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan. ktatsumi@naramed-u.ac.jp.ORCID http://orcid.org/0000-0002-4732-1093
Nara Medical University · JPKM Biologics (Japan) · JPUniversity of North Carolina at Chapel Hill · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relationship between von Willebrand factor (VWF) and inflammation has attracted considerable attention in recent years. VWF, which is stored in the Weibel-Palade bodies (WPBs) of endothelial cells (ECs), is released from WPBs in response to inflammatory stimuli and is thought to contribute to inflammation by promoting leukocyte extravasation. In this study, lung injury model mice were produced by intratracheal injection with lipopolysaccharides. The severity of lung inflammation was evaluated in mice with different genotypes (wild-type, Vwf

Indexed as

Lung InjuryPneumoniaADAMTS13 ProteinAnimalsEndothelial CellsHumansInflammationLipopolysaccharidesMicevon Willebrand FactorADAMTS13 ProteinADAMTS13 protein, humanADAMTS13 protein, mouseLipopolysaccharidesvon Willebrand FactorADAMTS13InflammationLipopolysaccharidesLungVon Willebrand factor

Identifiers

PMID37759076
OpenAlexW4387093407

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.